Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. [electronic resource]
Producer: 20140422Description: 730-5 p. digitalISSN:- 1876-4479
- Adalimumab
- Adolescent
- Adult
- Aged
- Anti-Inflammatory Agents, Non-Steroidal -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- C-Reactive Protein -- metabolism
- Child
- Child, Preschool
- Colitis, Ulcerative -- drug therapy
- Colonoscopy
- Crohn Disease -- drug therapy
- Disease-Free Survival
- Drug Therapy, Combination
- Feces -- chemistry
- Female
- Humans
- Immunosuppressive Agents -- therapeutic use
- Infliximab
- Leukocyte L1 Antigen Complex -- analysis
- Maintenance Chemotherapy
- Male
- Middle Aged
- Retrospective Studies
- Severity of Illness Index
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.